Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Guggenheim

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by equities researchers at Guggenheim from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports.

VIGL has been the topic of a number of other reports. Citigroup cut shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Wedbush lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and dropped their price objective for the company from $13.00 to $8.00 in a research note on Thursday, May 22nd. JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. HC Wainwright reduced their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Finally, William Blair downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Nine investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $11.50.

Vigil Neuroscience Trading Down 0.1%

Shares of Vigil Neuroscience stock traded down $0.01 on Thursday, hitting $7.88. The stock had a trading volume of 2,108,758 shares, compared to its average volume of 642,726. The stock has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The company's 50 day moving average price is $2.31 and its 200 day moving average price is $2.31.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Analysts predict that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Large investors have recently modified their holdings of the business. BVF Inc. IL grew its holdings in Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock worth $7,144,000 after acquiring an additional 2,200,000 shares during the period. 683 Capital Management LLC lifted its holdings in Vigil Neuroscience by 24.3% in the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock valued at $3,097,000 after acquiring an additional 340,000 shares during the period. Aberdeen Group plc boosted its position in shares of Vigil Neuroscience by 226.3% during the 1st quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock worth $3,070,000 after purchasing an additional 1,196,048 shares in the last quarter. Blair William & Co. IL grew its stake in shares of Vigil Neuroscience by 219.1% during the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after purchasing an additional 709,677 shares during the period. Finally, Woodline Partners LP grew its stake in shares of Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after purchasing an additional 344,614 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.